Bli medlem
Bli medlem

Du är här

2016-10-27

Adaptimmune Therapeutics plc: Adaptimmune Announces Collaboration with MSD to Evaluate KEYTRUDA® (pembrolizumab) in Combination with NY-ESO SPEAR® T-Cell Ther

PHILADELPHIA and OXFORD, United Kingdom, Oct. 27, 2016 (GLOBE NEWSWIRE) --
Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to
treat cancer, today announced that it has entered into a clinical trial
collaboration agreement with Merck&Co., Inc., Kenilworth, NJ, USA (known as
MSD outside the US and Canada), for the assessment of Adaptimmune's NY-ESO
SPEAR® (Specific Peptide Enhanced Affinity Receptor) T-cell therapy in
combination with MSD's anti-programmed death-1 (PD-1) inhibitor, KEYTRUDA®
(pembrolizumab), in patients with multiple myeloma. The study will evaluate
the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of
the combination, and is planned for initiation in 1H 2017.

Adaptimmune's SPEAR T-cell candidates are novel cancer immunotherapies that
have been engineered to target and destroy cancer cells. Its NY-ESO SPEAR
T-cell therapy has previously been evaluated in multiple myeloma in a single
agent Phase I/II trial in which 20 out of 22 patients (91 percent)
experienced a response at day 100 post autologous stem cell transplant.
KEYTRUDA is a humanized monoclonal antibody that works by increasing the
ability of the body's immune system to help detect and fight tumor cells.
KEYTRUDA blocks the interaction between PD-1 and its ligands, PD-L1 and
PD-L2, thereby activating T lymphocytes which may affect both tumor cells and
healthy cells. Blocking this interaction is reported to enable T-cell
activation and potentiates antitumor activity.

"In initial single-agent studies of our NY-ESO SPEAR T-cell therapy in
patients with advanced myeloma in the context of stem cell transplantation,
we have seen encouraging evidence of antitumor effect, safe administration
and prolonged persistence of transduced cells," said Rafael Amado,
Adaptimmune's chief medical officer. "KEYTRUDA has shown preliminary evidence
of activity in multiple myeloma, and there is preclinical evidence to support
the view that the combination of NY-ESO SPEAR T-cell therapy and anti-PD1
therapy may lead to meaningful anti-tumor activity. We look forward to
evaluating our therapy alone and in combination with KEYTRUDA in a randomized
trial of patients with multiple myeloma who are refractory or have relapsed
with standard therapy. "

The agreement is between Adaptimmune and Merck&Co., Inc., Kenilworth, NJ, USA,
through a subsidiary. Under the agreement, the trial will be sponsored by
Adaptimmune. The agreement also includes provision for potential expansion to
include Phase III registration studies in the same indication. Additional
details were not disclosed.

About Multiple Myeloma

Multiple myeloma is a cancer formed by malignant plasma cells. Normal plasma
cells are found in the bone marrow and are an important part of the immune
system, which is made up of several types of cells that work together to
fight infections and other diseases. Multiple myeloma is characterized by
several features, including low blood counts, bone and calcium problems,
infections, kidney problems, monoclonal gammopathy, and others; and by the
proliferation of these plasma cells within bone marrow. The American Cancer
Society estimates that approximately 30,300 new cases will be diagnosed in
the United States in 2016. Average five-year survival rates are estimated to
be approximately 45 percent with survival rates depending on factors such as
age, stage of diagnosis and suitability for auto-SCT, which is used as part
of the treatment for eligible patients with multiple myeloma. Despite recent
therapeutic advances, multiple myeloma remains an incurable but treatable
cancer. Patients are typically treated with repeat rounds of combination
therapy with the time intervals to relapse becoming shorter with each
successive line of therapy. The majority of patients eventually have a
relapse which cannot be further treated.

About Adaptimmune's TCR Technology

Adaptimmune's proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor)
T-cell receptor (TCR) technology enables the company to genetically optimize
TCRs, equipping them to recognize cancer antigens that are presented in small
quantities on the surface of a cancer cell, whether of intracellular or
extracellular origin, thus initiating cell death. The company's
differentiated, proprietary technology allows it to reliably generate
parental TCRs to naturally presented targets, affinity optimize its TCRs to
bind cancer proteins from solid and hematologic cancers that are generally
unavailable to naturally occurring TCRs, and to significantly reduce the risk
of side effects resulting from off-target binding of healthy tissues.

About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its SPEAR® (Specific Peptide Enhanced
Affinity Receptor) T-cell platform. Established in 2008, the company aims to
utilize the body's own machinery - the T-cell - to target and destroy cancer
cells by using engineered, increased affinity TCRs as a means of
strengthening natural patient T-cell responses. Adaptimmune's lead program is
a SPEAR T-cell therapy targeting the NY-ESO cancer antigen. Its NY-ESO SPEAR
T-cell therapy has demonstrated signs of efficacy and tolerability in Phase
1/2 trials in solid tumors and in hematologic cancer types, including
synovial sarcoma and multiple myeloma. Adaptimmune has a strategic
collaboration and licensing agreement with GlaxoSmithKline for the
development and commercialization of the NY-ESO TCR program. In addition,
Adaptimmune has a number of proprietary programs. These include SPEAR T-cell
therapies targeting the MAGE-A10 and AFP cancer antigens, which both have
open INDs, and a further SPEAR T-cell therapy targeting the MAGE-A4 cancer
antigen that is in pre-clinical phase with IND acceptance targeted for 2017.
The company has identified over 30 intracellular target peptides
preferentially expressed in cancer cells and is currently progressing 12
through unpartnered research programs. Adaptimmune has over 250 employees and
is located in Oxfordshire, U.K. and Philadelphia, USA. For more information:
http://www.adaptimmune.com

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995 (PSLRA). These
forward-looking statements involve certain risks and uncertainties. Such
risks and uncertainties could cause our actual results to differ materially
from those indicated by such forward-looking statements, and include, without
limitation: the success, cost and timing of our product development
activities and clinical trials and our ability to successfully advance our
TCR therapeutic candidates through the regulatory and commercialization
processes. For a further description of the risks and uncertainties that
could cause our actual results to differ materially from those expressed in
these forward-looking statements, as well as risks relating to our business
in general, we refer you to our Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission (SEC) on August 8, 2016, and our other SEC
filings. The forward-looking statements contained in this press release speak
only as of the date the statements were made and we do not undertake any
obligation to update such forward-looking statements to reflect subsequent
events or circumstances.

KEYTRUDA® is a registered trademark of Merck Sharp&Dohme Corp., a subsidiary
of Merck&Co., Inc., Kenilworth, NJ, USA.

Adaptimmune Contacts

Will Roberts
Vice President, Investor Relations
T: (215) 825-9306
E: will.roberts@adaptimmune.com

Juli P. Miller, Ph.D.
Associate Director, Investor Relations
T: (215) 825-9310
E: juli.miller@adaptimmune.com

Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mob: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.